perspectives
We are passionate about using our voices to advance our mission of developing life-transforming therapies for people living with serious muscle diseases.
We are passionate about using our voices to advance our mission of developing life-transforming therapies for people living with serious muscle diseases.
Sep 15, 2022
Lessons Learned on Preparing to Weather the Inevitable Challenges in Biotech
by Joshua Brumm,
President & CEO of Dyne
Read more
President & CEO of Dyne
Oct 7, 2021 |
From the Trenches: A LifeSci VC blog
by Josh Brumm
Read moreSep 15, 2021 | Blog
Starting a New Tradition of Support
by Molly White, Dyne’s vice president, global head of patient advocacy and engagement
Read moreJul 8, 2021 |
Playing To Win: Building A Position Of Strength In Biotech
by Josh Brumm
Read moreApril 28, 2021 | BLOG
Toward a brighter future: targeting the genetic basis of rare muscle diseases
By Romesh Subramanian, Ph.D.
Read moreApril 8, 2021 | BLOG
Scaling culture with growth: how to maintain your startup’s “special sauce”
By Joshua Brumm
Read moreJan 8, 2021 | Life Science Leader panel
Preparing to pitch in a virtual world
Featuring Joshua Brumm
WatchDec 16, 2020 | BLOG
Beyond the balance sheet: thinking broadly about dilution in building a transformative biotech
By Joshua Brumm
Read moreDec 14, 2020 | BLOG
Voice of the patient – the biopharma perspective
By Molly White
Read moreOct 21, 2020 | PODCAST
FSHD Society Radio
By Molly White
ListenAdditional content
Hear more from Dyne Therapeutics
Hear more from our CEO, Joshua Brumm
These milestones represent the significant and urgent need for new treatments for people with #DMD. We look forward to working with the community and regulators to deliver a potentially transformative therapy for this devastating disease.
